Bioblast Pharma Ltd  

(Public, NASDAQ:ORPN)   Watch this stock  
Find more results for ORPN
-0.01 (-0.18%)
Feb 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.73 - 2.82
52 week 1.49 - 6.05
Open 2.75
Vol / Avg. 18,342.00/437,496.00
Mkt cap 9.42M
P/E     -
Div/yield     -
EPS -2.57
Shares 3.34M
Beta 0.37
Inst. own 18%
Feb 22, 2018
Q4 2017 Bioblast Pharma Ltd Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '17) 2016
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -87.70% -102.88%
Return on average equity -101.46% -120.33%
Employees 19 -
CDP Score - -


15th Floor, 37 Dereh Menachem Begin St.
TEL AVIV-YAFO, 6522042
+972-3-7326616 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Bioblast Pharma Ltd (BioBlast) is an Israel-based development-stage biopharmaceutical company. The Company is focused on the identification, licensing, acquisition, development and commercialization of drugs for rare and ultra-rare genetic and metabolic diseases. It focuses on therapeutic platforms that offer solutions for several diseases that share a common pathophysiological mechanism, which are the functional changes that accompany a particular syndrome or disease. It also focuses on diseases with severe and debilitating manifestations. The Company has several drug candidates in clinical or preclinical development targeting neuromuscular/central nervous system (CNS) and mitochondrial diseases. Its drug candidates include Trehalose IV Solution, BB-FA (Bioblast-Friedreich's ataxia) and BBrm-02. The Company's product candidate platforms include Protein Stabilizing Platform, Read-through Platform and Mitochondrial Protein Replacement Platform.